FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093287410> ?p ?o ?g. }

• W3093287410 endingPage "3026" @default.
• W3093287410 startingPage "3026" @default.
• W3093287410 abstract "Background: Three PARPis (olaparib, niraparib and rucaparib) are currently FDA-approved as maintenance therapy in newly diagnosed and recurrent ovarian cancer. However, thus far, no trial has compared the three approved PARPis in the overall population, in patients with BRCA mutations, or in those with wild-type BRCA. Methods: A frequentist network meta-analysis was used for indirect comparisons between the different PARPis with respect to progression free survival (PFS), overall survival (OS), and adverse events. Results: Overall, six randomized clinical trials involving 2,770 patients, were included in the analysis. Results from the indirect comparisons revealed no statistically significant differences between the three PARPis with respect to PFS or OS in the entire population and in patients with mutated and wild-type BRCA, separately. Niraparib showed a statistically significant increased risk for grade 3 and 4 thrombocytopenia (risk-difference [RD] from placebo: 0.3; 95% confidence interval [CI], 0.27‒0.34) and any grade neutropenia (RD from placebo: 0.22; 95% CI, 0.18‒0.25) as compared with the other PARPis. Conclusion: No statistically significant difference was found between the three PARPis with respect to PFS or OS (overall and in subpopulations by BRCA status). There is, however, a statistical difference in toxicity as niraparib is associated with a greater risk for thrombocytopenia and neutropenia." @default.
• W3093287410 created "2020-10-22" @default.
• W3093287410 creator A5007458418 @default.
• W3093287410 creator A5013253348 @default.
• W3093287410 creator A5033865459 @default.
• W3093287410 creator A5038008488 @default.
• W3093287410 date "2020-10-18" @default.
• W3093287410 modified "2023-10-16" @default.
• W3093287410 title "Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis" @default.
• W3093287410 cites W1839388921 @default.
• W3093287410 cites W1996017104 @default.
• W3093287410 cites W2004943949 @default.
• W3093287410 cites W2019607817 @default.
• W3093287410 cites W2071966564 @default.
• W3093287410 cites W2130078242 @default.
• W3093287410 cites W2160466424 @default.
• W3093287410 cites W2171972386 @default.
• W3093287410 cites W2528228811 @default.
• W3093287410 cites W2550229146 @default.
• W3093287410 cites W2557717244 @default.
• W3093287410 cites W2603440970 @default.
• W3093287410 cites W2737389832 @default.
• W3093287410 cites W2754327139 @default.
• W3093287410 cites W2804717005 @default.
• W3093287410 cites W2883673963 @default.
• W3093287410 cites W2896628407 @default.
• W3093287410 cites W2897430921 @default.
• W3093287410 cites W2906986535 @default.
• W3093287410 cites W2922503148 @default.
• W3093287410 cites W2931860768 @default.
• W3093287410 cites W2944149590 @default.
• W3093287410 cites W2945098772 @default.
• W3093287410 cites W2946448900 @default.
• W3093287410 cites W2970684805 @default.
• W3093287410 cites W2972664697 @default.
• W3093287410 cites W2975141952 @default.
• W3093287410 cites W3006045662 @default.
• W3093287410 cites W4210987384 @default.
• W3093287410 cites W4211203170 @default.
• W3093287410 doi "https://doi.org/10.3390/cancers12103026" @default.
• W3093287410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7603267" @default.
• W3093287410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33081005" @default.
• W3093287410 hasPublicationYear "2020" @default.
• W3093287410 type Work @default.
• W3093287410 sameAs 3093287410 @default.
• W3093287410 citedByCount "11" @default.
• W3093287410 countsByYear W30932874102021 @default.
• W3093287410 countsByYear W30932874102022 @default.
• W3093287410 countsByYear W30932874102023 @default.
• W3093287410 crossrefType "journal-article" @default.
• W3093287410 hasAuthorship W3093287410A5007458418 @default.
• W3093287410 hasAuthorship W3093287410A5013253348 @default.
• W3093287410 hasAuthorship W3093287410A5033865459 @default.
• W3093287410 hasAuthorship W3093287410A5038008488 @default.
• W3093287410 hasBestOaLocation W30932874101 @default.
• W3093287410 hasConcept C104317684 @default.
• W3093287410 hasConcept C121608353 @default.
• W3093287410 hasConcept C126322002 @default.
• W3093287410 hasConcept C142724271 @default.
• W3093287410 hasConcept C143998085 @default.
• W3093287410 hasConcept C182979987 @default.
• W3093287410 hasConcept C204787440 @default.
• W3093287410 hasConcept C27081682 @default.
• W3093287410 hasConcept C2776694085 @default.
• W3093287410 hasConcept C2777063308 @default.
• W3093287410 hasConcept C2779962180 @default.
• W3093287410 hasConcept C2780427987 @default.
• W3093287410 hasConcept C2908647359 @default.
• W3093287410 hasConcept C44249647 @default.
• W3093287410 hasConcept C54355233 @default.
• W3093287410 hasConcept C71924100 @default.
• W3093287410 hasConcept C82381507 @default.
• W3093287410 hasConcept C86803240 @default.
• W3093287410 hasConcept C95190672 @default.
• W3093287410 hasConcept C99454951 @default.
• W3093287410 hasConceptScore W3093287410C104317684 @default.
• W3093287410 hasConceptScore W3093287410C121608353 @default.
• W3093287410 hasConceptScore W3093287410C126322002 @default.
• W3093287410 hasConceptScore W3093287410C142724271 @default.
• W3093287410 hasConceptScore W3093287410C143998085 @default.
• W3093287410 hasConceptScore W3093287410C182979987 @default.
• W3093287410 hasConceptScore W3093287410C204787440 @default.
• W3093287410 hasConceptScore W3093287410C27081682 @default.
• W3093287410 hasConceptScore W3093287410C2776694085 @default.
• W3093287410 hasConceptScore W3093287410C2777063308 @default.
• W3093287410 hasConceptScore W3093287410C2779962180 @default.
• W3093287410 hasConceptScore W3093287410C2780427987 @default.
• W3093287410 hasConceptScore W3093287410C2908647359 @default.
• W3093287410 hasConceptScore W3093287410C44249647 @default.
• W3093287410 hasConceptScore W3093287410C54355233 @default.
• W3093287410 hasConceptScore W3093287410C71924100 @default.
• W3093287410 hasConceptScore W3093287410C82381507 @default.
• W3093287410 hasConceptScore W3093287410C86803240 @default.
• W3093287410 hasConceptScore W3093287410C95190672 @default.
• W3093287410 hasConceptScore W3093287410C99454951 @default.
• W3093287410 hasIssue "10" @default.
• W3093287410 hasLocation W30932874101 @default.
• W3093287410 hasLocation W30932874102 @default.

• next